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Abstract
S100A4 promotes cancer metastasis, but its overall status and splicing manner during gastrocarcinogenesis re-
mains less known. We therefore examined S100A4 frequencies, splicing pattern(s) and the underlying reason(s) for
S100A4 expression in gastric cancers. Immunohistochemistry revealed frequent S100A4 expression in intestinal
gastric cancers (37/45; 82%) and diffuse gastric cancers (12/20; 60%), but uncommon in noncancerous epithelia
(0/12), chronic gastritis (2/24; 8%), and intestinal metaplasia (3/15; 20%). Of 65 primary tumors, 18 were found with
focal S100A4 expression, while their LN metastases showed homogenous distribution. S100A4-oriented reverse
transcription–polymerase chain reaction yielded a transcript containing exons 1, 3, and 4 (AS1) in 20% of noncan-
cerous, 84% premalignant, and 92% tumor tissues and a transcript harboring exons 1 to 4 (AS2) in 65% of gastric
cancers (GCs), 26% premalignant but none in noncancerous tissues. Further analyses found AS1 expression in stro-
mal but not epithelial cells of premalignant tissues, absence of AS2 in endoscopic inflammatory mucosa, and the
coexistence of AS1/AS2 in the cultured fibroblasts. Methylation DNA sequencing revealed hypermethylation of four
critical CpG sites within S100A4 intron first among S100A4-negative gastric tissues and hypomethylation in S100A4-
expressing GC tissues/cell lines. E-cadherin reduction and Wnt activation were common in gastric cancers, which
were closely correlated but unnecessarily overlapped with S100A4 expression. Our findings suggest that S100A4
expression is closely related with GC formation, which, as a hypomethylation event, is accompanied with E-cadherin
reduction and Wnt activation. The preferential S100A4 AS2 expression in GC cells would have potential values in GC
surveillance and prognostic assessment.
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Introduction
Gastric cancer (GC) is one of the commonest malignancies in the
world and the major cause of cancer-related deaths in China [1]. The
prognosis of GCs remains poor owing to its later diagnosis and strong
tendency of local invasiveness and distal metastasis [2]. Therefore,
exploration of genetic alterations closely linked with GC formation
and dissemination would be of great value in prevention, early detec-
tion, and prognostic evaluation of this malignancy.
S100A4 protein is the well-studied member of S100 family [3]. It
is also named as metastasis-associated Mts1 and fibroblast-specific
protein 1 (FSP1) because of its close association with cancer metasta-
sis and constitutive expression in fibroblasts [4,5]. Moreover, S100A4
exerts multiple biological effects on proliferation and apoptosis, cell
motility and adhesion, extracellular matrix remodeling, and angio-
genesis of cancer cells [6]. For example, transfection of S100A4 could
enhance the metastatic potential of bladder and mammary carcinoma
cells [7,8], whereas blockage of its expression could reduce cancer
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metastatic capacity [9]. Although the tumor-promoting effects of
S100A4 have been documented in a variety of cancers, no report
has been so far available concerning the pattern(s) of S100A4 expres-
sion during stepwise gastrocarcinogenesis and in the primary and sec-
ondary gastric cancers.
Alternative splicing (AS) is a process by which the exons of pri-
mary transcripts (pre-mRNA) from genes can be spliced in different
arrangements to produce structurally and, in most cases, functionally
distinct mRNA and protein variants [10]. Several splicing variants of
S100A4 gene have been reported, of which two isoforms with Exons
1, 3, and 4 (AS1) and with Exons 2, 3, and 4 (AS2) were well docu-
mented [11,12]. According to the Gene Database [www.ncbi.nlm.
nih.gov/entrez], the translation starting point of S100A4 mRNA
was located at the Codon 1013 in Exon 3 rather than in Exon 1
or 2, resulting in the same protein when AS1 or AS2 was used as
translation templates. For this reason, more efforts were paid to in-
vestigate the oncogenic effects of S100A4 protein; consequently, the
genetic implication and prognostic value(s) of these two splicing var-
iants in human cancers had long been overlooked.
So far, several molecular alterations have been proposed to be re-
sponsible for S100A4 up-regulation. E-cadherin is an important ad-
hesion molecule that distributes widely in epithelial cells. This
protein is regarded as an invasion suppressor, because loss of func-
tional membranous E-cadherin results in epithelial-mesenchymal
transition, a precedent condition of cancer dissemination [13]. An
inverse relationship of S100A4 and E-cadherin expressions was found
in some types of cancers including gastric cancer [14], which was
closely related with the poorer outcome of cancer patients. However,
it is still unclear whether these two alterations are directly linked or
indirectly paralleled. Recent data obtained from cultured colorectal
cancer cells suggested that S100A4 was the target of Wnt signaling
because S100A4 promoter contains a T-cell factor (TCF) binding site
that could be activated by β-catenin, providing a cue for Wnt-oriented
antimetastasis approach [15]. Nevertheless, similar in vivo findings
have not yet been available. DNA methylation is a common epigenetic
event for regulating gene transcription [16]. The data from other
cancer types reveal frequent hypomethylation of CpG sites in the first
intron of S100A4 gene [17], but the casual relationship of this event
with gene reactivation has not yet been well ascertained and no datum
has been so far available to correlate S100A4 up-regulation with hypo-
methylation in gastric cancers.
On the basis of the above unclear issues, the current study aimed
to profile expression incidence and splicing pattern(s) of S100A4
during stepwise gastrocarcinogenesis and to elucidate the underlying
reason(s) that account for S100A4 expression using a panel of gastric
samples in different morphologies and from different sources.
Materials and Methods
Sample Collection and Treatment
Sixty-five gastric cancer cases were selected from the Frozen Gas-
tric Tissue Bank in Liaoning Laboratory of Cancer Genomics, Dalian
Medical University (DMU). They were obtained from the operat-
ing rooms of DMU-Affiliated Hospitals after getting patients’ con-
sents. The tissues were chosen and incised carefully from the tumor
mass, tumor-surrounding tissue, and grossly normal-looking epithe-
lium, respectively. They were trimmed into suitable sizes on ice,
snap-frozen immediately in liquid nitrogen, and stored at −80°C
until use. All treatments were done within 20 minutes after removal.
Regional lymph nodes were obtained during operation and fixed in
10% formaldehyde for pathological diagnosis and then for experi-
mental purposes. After getting patients’ consent, fresh endoscopic
gastric biopsies of 18 GC-free patients were collected from the Gas-
troendoscopic Department of DMU Second Affiliated Hospital. The
samples were initially used for Helicobacter pylori test and then for
research purposes. The tonsil specimens removed by conventional
tonsillectomy were treated in the same manner and used as S100A4-
positive controls [6] in immunohistochemical (IHC) staining, reverse
transcription–polymerase chain reaction (RT-PCR), and Western blot
analysis. After getting donor’s consent, the culture of normal fibro-
blasts was conducted using a piece of normal skin specimen removed
for cosmetological purpose. The cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS). The cells were harvested and used as S100A4-positive control
in immunocytochemical (ICC), protein, and RNA evaluations.
Hematoxylin and eosin staining and morphologic reexamination
were performed on each of the frozen tissue blocks before further
experiments. When the blocks showed homogeneous composition,
they were sectioned directly for RNA and protein isolations followed
by frozen tissue array construction. Otherwise, the target histologic
region(s) were defined and sampled for cell type–defined sample
preparations and tissue array construction by the methods described
elsewhere [18]. RNA isolation was performed on the tiny endoscopic
biopsies without cell discrimination.
Cell Culture and Treatment
Human gastric cancer cell lines MGC803 and BGC823 were cul-
tured in DMEM (Gibco, Los Angeles, CA) containing 10% FBS at
37°C in 5% CO2. After getting donor’s consent, the culture of nor-
mal fibroblasts was conducted using a piece of normal skin specimen
removed for medical cosmetic purpose. The cells were incubated
only or cocultured with GC cells in DMEM containing 10% FBS
and were used as S100A4-positive control. The cells were harvested
for DNA, RNA, and protein preparations when closing to 80% of
confluence. For ICC and immunofluorescence examinations, gelatin-
coated coverslips were put onto the dishes before initial cell seeding.
The cells were harvested for ICC and immunofluorescence staining,
RNA isolation, and protein extractions when they reached a semi-
confluent state.
Tissue Array–Based Immunohistochemical Staining
The representative donor tissues were sampled by coring needles
under −30°C and embedded orderly into a frozen recipient block
prepared from fresh chicken muscle (Chinese Invention Patent:
02109826.3) to create frozen tissue microarrays. The frozen tissue
microarrays with densities of 36 or 56 spots/cm2 were sectioned to
5-μm thickness for IHC profiling. The antibodies used were as fol-
lows: a rabbit anti–human polyclonal antibody that specifically rec-
ognized S100A4 out of other members in S100 family (Lab Vision &
Neomarkers, Fremont, CA; 1:100), a mouse anti–human–E-cadherin
monoclonal antibody (NCH-38; DAKO, North America Inc. CA;
1:120), a goat anti–human Wnt2 polyclonal antibody (Santa Cruz
Biotech, Santa Cruz, CA; 1:100), a rabbit anti–human–TCF4 poly-
clonal antibody (Santa Cruz Biotech; 1:120), and a mouse anti–-
human–β-catenin monoclonal antibody (Santa Cruz Biotech; 1:100).
The microarray sections lacking incubation with individual primary
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antibodies were used as background controls. The staining results
were evaluated by two researchers, with the density of immunolabel-
ing scored as negative (−) if no immunolabeling was observed in tar-
get cells, weakly positive (+) if the labeling was faint, moderately (++)
to highly positive (+++) when the labeling was distinctly strong than
(+), or focally positive (F+ ∼ +++) if only part of target cells showed +
and/or >++ staining patterns.
RNA Extraction and RT-PCR
Sample RNA were isolated from defined histologic regions of fro-
zen tissue blocks, using TRIzol Reagent (Life Tech, Grand Island,
NY). Reverse transcription–polymerase chain reaction was performed
using Takara RNA PCR kit (AMV) version 2.1 (Takara Biotech Inc,
Dalian, China) under the following conditions: 0.8 μg of total RNA
was reverse-transcribed with random primer at 55°C for 30 minutes
in a 20-μl solution; the reaction was terminated by incubating the
mixture at 99°C for 5 minutes. S100A4 was amplified using a pair of
primers: sense, 5′-TCA GAA CTA AAG GAG CTG CTG ACC -3′;
antisense, 5′-TTT CTT CCT GGG CTG CTT ATC TGG -3′.
Polymerase chain reaction was performed with 30 cycles at 94°C
for 4 minutes, 94°C for 45 seconds, 59°C for 45 seconds, and 72°C
for 1 minute, followed by final extension at 72°C for 7 minutes [19].
The splicing variants of S100A4 (Figure 1) were amplified by two
pairs of primers (sense AS1, 5′-CTC TCT ACA ACC CTC TCT
CC-3′; sense AS2, 5′-GCA CAC GCT GTT GCT ATA GTA C-3′,
antisense AS1/AS2, 5′-GGA AGA CAC AGT ACT CTT GG-3′)
under the condition with 35 cycles at 95°C for 4 minutes, 55°C for
45 seconds, and 72°C for 1.5 minutes, followed by 72°C for 7 minutes
for the final extension. β-Actin products generated from the same RT
solution were referred as internal quantity controls. To clearly dem-
onstrate 9 base pair (bp) difference between AS1 (287 bp) and AS2
(278 bp), the two kinds of PCR products were separated in 6% poly-
acrylamide gels (containing 6 ml of H2O, 2 ml of 5 × Tris-borate-
EDTA solution, 2 ml of 30% acrylamide, 70 μl of 10% ammonium
persulfate, and 6 μl of 4N -tetramethylethylenediamine) and photo-
graphed with the automatic UV illuminator (Bio-spectrum Imaging
System; UVP, Inc., Upland, CA).
Protein Preparations and Western Blot Analyses
Eight to sixteen pieces of 5-μm dissected fragments from defined
frozen tissue regions were collected for protein preparations. They
were put into 1.5-ml Eppendorf tube containing 150 μl of prechilled
2 × Laemmli SDS sample buffer containing 0.125 M Tris-HCl pH 6.8,
4% SDS, 20% v/v glycerol, and 0.2 M dithiothreitol. After being
homogenized by ultrasonic vibration (UP200s; Hielscher GmbH,
Mannheim, Germany), the samples were heated in boiling water
for 5 minutes. Cell lysates were centrifuged for 4 to 5 minutes at
15,000 rpm, and the protein-containing supernatants were removed
to fresh tubes for experimental purposes.
ForWestern blot analysis, the 50-μg protein samples were separated
in 10% SDS-PAGE gel and then transferred to polyvinylidene di-
fluoride membrane (Amersham Inc., Buckinghamshire, UK). The
membrane was blocked with 5% skimmilk (Becton Dickinson France
SA, Le Pont-de-Claix, France) in TBS at 4°C overnight, incubated at
room temperature for 1 hour with the first antibodies recognizing
human S100A4 (Santa Cruz Biotech) and for another hour with horse-
radish peroxidase–conjugated goat antimouse IgG. The bound anti-
body was detected using the enhanced chemiluminescence (ECL)
system (Roche GmbH, Mannheim, Germany). After removing the
labeling signal by incubating with stripping buffer (62.5 mM Tris-
HCl, pH 6.7, 100 mM 2-mercaptoethanol, 2% SDS) at 55°C for
30 minutes, the membrane was reprobed with E-cadherin and then
with β-actin using the same experimental procedures.
Identification of the Source of S100A4 Variants
To identify the source of S100A4 variants in the premalignant and
noncancerous mucosa, RNA samples were isolated from the total
mucosa, stromal components (mainly lymphocytes), and relative
pure epithelial cells of three representative chronic gastritis that were
S100A4-positive in RT-PCR and Western analyses but showed vari-
able S100A4 staining patterns among different cell components of
the tissue sections. Briefly, the target stromal and epithelial regions
in hematoxylin and eosin–stained slides were determined under the
microscope and its margin was marked in a series of tiny spots inked
with a special instrument named Lencil (Chinese Inventive Patent:
02109826.3), a lens-like device fixed on the light microscope with
a spray tip that could mark the center of the visual field exactly when
upward pressure was formed by gently attaching the slide with the
spray tip. Referring to the marks on the section, the border of target
region in the frozen tissue block was incised with a rotation mini-
knife (Chinese Inventive Patent: 02109826.3) in the depth of 0.1
to 0.2 mm. By this way, the target fragment separated from the main
part during frozen section. According to the size of target region, 6 to
10 pieces of 7-μm frozen fragments were collected immediately by an
autoclaved tip wetted with cold TRIsol (Gibco) for RNA isolation.
The sample RNA were amplified with the primers for AS1 and AS2
transcripts and separated in 6% polyacrylamide gel. The RNA sam-
ples isolated from human tonsil and cultured human fibroblasts were
used as controls of stroma-associated S100A4 variant(s).
Figure 1. Layout of the composition of splicing variants AS1 and AS2, the site of S100A4 promoter and the locations of PCR primers for
AS1 and AS2 amplification.
Translational Oncology Vol. 1, No. 4, 2008 S100A4 and Gastrocarcinogenesis Li et al. 167
Correlative Analyses of S100A4 Expression, E-cadherin
Reduction, and Wnt Activation
To evaluate the correlation of S100A4 with E-cadherin alterations
and Wnt activation, 27 gastric cancer samples (15 i-GC and 12 d-GC)
were selected from the 65 cases for a parallel study on the two pa-
rameters by the methods of IHC staining. The Kruskal-Wallis and
Mann-Whitney tests were used to analyze the relation of S100A4
and E-cadherin expression in different histologic groups. The Spearman
correlation test was used to determine the relationship between S100A4
expression and the extent of membranous E-cadherin reduction.
TCF4 and β-catenin nuclear cotranslocation is the end point of
Wnt signaling [20]. For this reason, this parameter was adopted
for evaluating potential association of S100A4 expression and acti-
vated Wnt signaling by checking intracellular distribution of TCF4,
β-catenin, and S100A4, respectively. The two established GC cell
lines, MGC803 and BGC823, were examined by S100A4 ICC stain-
ing combined with immunofluorescent double labeling for TCF4
and β-catenin. The cultured normal fibroblasts were used as positive
control for S100A4.
DNA Extraction and Methylation Sequencing
Altogether, 7 S100A4-negative gastric mucosa with mild chronic
inflammatory changes, 6 S100A4-negative GC tissues, 12 S100A4-
positive GC tissues, and 2 GC cell lines were selected for this assay.
DNA preparations were conducted in parallel with RNA isolation by
the method described above. Sixteen to 24 pieces of 3-μm target fro-
zen fragments were collected after sectioning and placed immediately
in a 1.5-ml Eppendorf tube containing 300 μl of Tris-EDTA buffer
(pH 8.0, 1% SDS), digested with 5 μl of proteinase K (10 mg/ml), and
subjected to conventional DNA extraction using phenol/chloroform
extraction and ethanol precipitation. For chemical DNA modifica-
tion, 5 μl of sample DNA (0.4 μg/μl) was mixed with 40 μl of pure
water, heated at 37°C for 10 minutes, and interacted with 5 μl of
2 M NaOH at 37°C for 10 minutes, mixed with 30 μl of freshly
prepared 10 mM hydroquinone (H9003; Sigma Chemical Inc., St.
Louis, MO) and 520 μl of 3 M sodium bisulfate (S9000; Sigma
Chemical Inc.), and then incubated under 50°C in darkness for 16
to 20 hours. The chemical-modulated sample DNA was subjected to
desalt purification using Wizard DNA Clean-Up System (A7280;
Promega Cooperation, Madison, WI). The purified DNA was dis-
solved with 50 μl of pure water, mixed with 5.5 μl of 3 M NaOH
at 37°C for 5 minutes, precipitated in ethanol, and dissolved in 30 μl
of pure water for use [31,32].
A pair of primers as follows was used for sequencing critical CpG
sites within the first intron of the S100A4 gene, according to the Gene
Database [www.ncbi.nlm.nih.gov/entrez]: S100A4-F, 5′-GTT TTT
TAG GTG TTT TTG AGA TGT G -3′; and S100A4-R, 5′-ACA
AAA ACC CAC AAT TAC CTT CTA C-3′. The region amplified
by the primers included four CG sites because the methylation status
of this site is related with the S100A4 expression [21]. The modified
DNA samples were amplified using Takara PCR amplification Kit
(Takara Biotech Inc.), and the products were sequenced in reverse
direction by Takara Biotech Inc. Dalian Branch with ABI PRISM
3730XL DNA Analyzer and ABI PRISM 377XL DNA sequencer.
Statistical Analyses
Kruskal-Wallis and Mann-Whitney tests were used to analyze the
differences of S100A4 detection and the incidences of AS1 and AS2
variants between 1) noncancerous mucosa and premalignant lesions
or GC tissues, 2) premalignant lesions and GC tissues, 4) intestinal
metaplasia and chronic gastritis, and 5) d-GCs and i-GCs and to elu-
cidate the relation of S100A4 with E-cadherin reduction and Wnt
activation in different histologic groups. The Spearman correlation
test was used to determine the relationship between S100A4 expres-
sion and the extent of membranous E-cadherin reduction as well as
TCF4 and β-catenin nuclear cotranslocation.
Results
Frequent Expression and Heterogeneous Distribution of
S100A4 in GCs
Histologic reevaluation was performed carefully on each of the tis-
sue blocks before further studies. Totally, 12 noncancerous mucosa,
39 premalignant (24 chronic gastritis and 15 intestinal metaplasia),
65 cancer tissues, and 26 lymph node metastases were checked immu-
nohistochemically. According to Lauren’s classification [22], the cancer
tissues were classified into two subtypes: relatively well-differentiated
intestinal gastric cancer (i-GC) and poorly differentiated diffuse gas-
tric cancer (d-GC). Of 65 GC tissues, 36 were found with distinct
heterogeneous composition and therefore subjected to tissue-defined
RNA and protein isolations to minimize cell-cell cross-contamination
[18]. The corresponding regions were then used for frozen tissue array
construction. The sample preparations were also performed on the
cultured fibroblasts and human tonsil specimens.
The results of array-based IHC staining were summarized in Table 1
and demonstrated in Figure 2A. It was found that the epithelial cells
in noncancerous tissues were negative in S100A4 expression, but the
stromal lymphocytes were stained positively; the detection rate of
S100A4 increased to 13% (5/39) in premalignant tissues and reached
to 75% (49/65) in cancer samples, especially those metastasized to
lymph nodes (26/26, 100%). Statistical analyses with Kruskal-Wallis
and Mann-Whitney tests revealed that S100A4 detection rate of
tumor tissues was significantly different with that of noncancerous
mucosa and premalignant lesions (P = .000) but neither between non-
cancerous and premalignant mucosa (P = .196) nor between i-GC
and d-GC (P = .057). The amount and distribution of S100A4
protein were not identical among the primary cancer tissues and some-
times in the same glandular structure, because some cells demonstrated
enhanced S100A4 immunolabeling, whereas others showed much
Table 1. TissueMicroarray-Based IHC Profiling of S100A4 Expression in Different Gastric Tissues.
Histologic diagnosis n S100A4 (%) P
− +/>++ Focal +∼+++
Noncancerous 12 12 (100) 0/0 (0/0) 0
Premalignant 39 34 (87) 4/1 (10/3) 0 .196*
Chronic gastritis 24 22 (92) 1/1 (4/4) 0
Intestinal metaplasia 15 12 (80) 3/0 (20/0) 0 .295‡
Gastric cancer 65 16 (25) 14/17 (21/26) 18 (28) .000*,†
i-GC 45 8 (18) 12/11 (27/24) 14 (31)
d-GC 20 8 (40) 2/6 (10/30) 4 (20) .057§
Lymph node metastases 26 0 (0) 26 (100)
i-GC 16 0 (0) 16 (100)
d-GC 10 0 (0) 10 (100)
*In comparison with noncancerous mucosa.
†In comparison with premalignant lesions.
‡In comparison with chronic gastritis.
§In comparison with i-GC.
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weaker, even negative, staining (Figure 2A; i-GC). This focal positive
phenomenon was found in 18 of 65 GCs so far checked (Table 1).
Conversely, all of the lymph node metastases were stained homog-
enously irrespective of the different S100A4 distribution in their pri-
mary tumors (Figure 2A; lymph node and Table 1).
Preferential Expression of S100A4 AS2 Variant in GC Cells
To validate the IHC data, Western blot and RT-PCR analyses were
performed on the protein and RNA samples isolated from 7 noncan-
cerous, 19 premalignant, and 26 cancer regions of 26 GC cases. As
shown in Figure 2B, S100A4 protein in 12 kDa could be observed in
i-GC and d-GC samples but was undetectable or was very weak in
their noncancerous or premalignant counterparts. The two major
forms of S100A4 splicing variants, AS1 and AS2, were amplified
from the same RT products under identical reaction condition. As
indicated in Table 2 and shown in Figure 3A, the detection rates
Figure 2. (A) Immunohistochemical illustration (original magnification, ×40) of S100A4 expression in noncancerous mucosum (N),
chronic gastritis (CG), intestinal metaplasia (IM), and a case of intestinal type gastric cancer (i-GC) with lymph node metastasis (LN+).
Human tonsil tissue was used as S100A4-positive control. Arrow indicates the gland shown in higher magnification (original magnification,
×80). (B) Evaluation of S100A4 expression in some gastric tissues by RT-PCR and Western blot analyses. β-Actin was used as quantitative
and qualitative control.
Table 2. Reverse Transcription–Polymerase Chain Reaction Detection of S100A4 Splicing Variants
(AS1 and AS2) in Different Gastric Tissues.
Histologic diagnosis n AS1 (%) P AS2 (%) P P
− + − +
Noncancerous 7 6 (86) 1 (14) 7 (100) 0 (0) .620*
Premalignant 19 3 (16) 16 (84) .030† 14 (74) 5 (26) .406† .002*
Gastric cancer 26 2 (8) 24 (92) .009† 9 (35) 17 (65) .019† .019*
.399‡ .010†
d-GC 12 0 (0) 12 (100) 3 (27) 8 (73) .069*
i-GC 15 2 (13) 13 (87) .574§ 6 (40) 9 (60) .610‡ .104*
GC-free biopsies¶ 18 0 (0) 18 (100) 15 (87) 3 (13) .000*
GC cell lines 2 0 (0) 2 (100) 0 (0) 2 (100)
*In comparison with AS1.
†In comparison with noncancerous mucosa.
‡In comparison with premalignant lesions.
§In comparison with i-GC.
¶RNAs were isolated without cell discrimination.
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of AS1 transcript were 14% (1/7) among noncancerous mucosa,
86% (16/19) among premalignant lesions, and 92% (24/26) among
cancer tissues including 100% (11/11) of i-GC and 87% (13/15) of
the d-GC samples. The frequencies of AS1 expression were signifi-
cantly different between noncancerous and premalignant (P = .030)
or GC tissues (P = .009) but not between premalignant and GC
tissues (P = .399). AS2 was undetectable in noncancerous epithelia
(0/7) but became detectable in 26% (5/19) of premalignant tissues
and in 66.6% (18/27) of GCs. The frequencies of AS2 detection
were significantly different either between noncancerous and GC
tissues (P = .019) or between premalignant and GC samples (P =
.010). The differences of AS2 detection between noncancerous and
premalignant tissues and between i-GCs and d-GCs were not statis-
tically significant (P = .406 and P = .610, respectively). Additionally,
the levels of AS1 and AS2 expression vary with the samples except in
cultured fibroblasts (Figure 3B).
S100A4 Splicing Patterns Vary with Cell Types
RNA samples were isolated from human tonsil, the total speci-
mens, and the defined regions of stromal lymphoid nodules and
epithelial layers of some chronic gastritis and cultured normal fibro-
blasts, respectively. By the use of those RNA samples, the sources of
AS1 and AS2 variants in premalignant lesions and S100A4 splicing
patterns in different cell types were characterized by RT-PCR and
PAGE assay. As shown in Figure 3, A and B, only the AS1 product
could be detected in the sample RNA isolated from the tonsil and
the lymphoid nodules (L) of chronic gastritis. The AS1 product
was also detectable from the RNA samples isolated from the total
premalignant specimen (L/E) but not from the epithelial cells (E).
However, both AS1 and AS2 products were generated in almost
equal amounts from the cultured fibroblasts (Figure 3A, a–c). Among
the tissue samples so far checked, no case was found with only the
AS2 expression (AS1−/AS2+).
Rarity of AS2 in Inflammatory Mucosa of GC-Free Patients
RNA samples were prepared from gastric mucosa of 18 GC-free
patients without cell discrimination. Reverse transcription–polymerase
chain reaction analyses for AS1 and AS2 revealed that AS1 transcript
could be detected in those samples (Figure 3A, a–c, and Table 2),
whereas a very faint AS2 band was observed only in a few of samples
Figure 3. (A) The numbers and percentages of AS1−/AS2−, AS1+/AS2−, and AS1+/AS2+ cases in noncancerous epithelia, premalig-
nant lesions, intestinal gastric cancer (i-GC), diffuse gastric cancer (d-GC) groups, and among the endoscopic gastric mucosa obtained
from GC-free patient. AS1−/AS2+ splicing pattern is not found in the samples so far checked. (B) Characterization of AS patterns of
S100A4 in noncancerous, premalignant, and cancer tissues of the stomach (a), the main components of chronic gastritis tissue obtained
from GC patient (b) and endoscopic mucosa of GC-free patients (c) by RT-PCR and polyacrylamide gel electrophoresis. Human tonsil and
cultured normal fibroblasts were used as S100A4-positive controls. Arrows indicate the samples with AS2 expression.
Table 3. Level of S100A4 Expression and Abundance of Membranous E-cadherin and Nuclear β-Catenin in Different Gastric Tissue.
Histologic Diagnosis n S100A4 P E-cadherin P Nuclear β-Catenin P
− + ++ +++ − + >++ − + ++ +++
Noncancerous 7 7 0 0 0 0 0 7 7 0 0 0
Premalignant 27 26 0 1 0 5 9 13 21 4 1 1
Chronic gastritis 16 15 0 1 0 3 4 9 13 2 0 1
Intestinal metaplasia 11 11 0 0 0 .801* 2 5 4 .527* 8 2 1 0 .501*
Gastric cancer 27 6 10 8 3 .000† 10 14 3 .007† 1 13 8 5 .000†
i-GC 15 2 5 6 2 4 10 1 1 6 5 3
d-GC 12 4 5 2 1 .152‡ 6 4 2 .131‡ 0 7 3 2 .755‡
*In comparison with chronic gastritis.
†In comparison with premalignant lesions.
‡In comparison with i-GC.
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(3/18). In contrast, sufficient amounts of AS1 and AS2 products were
generated from the sample RNA of normal fibroblasts. Similar with
the findings in noncancerous mucosa of GC patients, IHC staining
demonstrated that the lymphocytes and sporadically distributed fibro-
blasts in the stromal space but not epithelial cells were positive in
S100A4 expression (data not shown).
Inverse S100A4 and E-cadherin Expressions Are Not
Always Overlapped
In parallel with the S100A4 examination, the status of membranous
E-cadherin expression in different gastric tissues was evaluated im-
munohistochemically. As shown in Table 3, membranous E-cadherin
remained intact (++∼+++) in all noncancerous (7/7) and in most
premalignant lesions (13/20, 52%) but became decreased (+) and
even diminished (−) in 89% (24/27) of GCs. The difference of mem-
branous distribution of E-cadherin is significant between the two
groups (P = .007). Although correlative analyses of S100A4 and
E-cadherin expressions (Table 4) revealed a general inverse relation-
ship among the cancer and premalignant samples so far checked
(P = .043, r = −0.282), there were two cases of GCs with S100A4
up-regulation and almost unchanged level of E-cadherin expression
and, conversely, 7 of 54 cases (2 GC and 5 premalignant tissues) with
neither E-cadherin nor S100A4 expression. As demonstrated in
Figure 4A, E-cadherin was generally distributed in glandular crypts
of an i-GC case but part of cells showed S100A4 expression. Fur-
thermore, both MGC803 and BGC823 cells expressed S100A4,
whereas the former showed almost intact membranous E-cadherin
(Figure 4B).
S100A4 Expression and Wnt Activation Were Not
Well Matched
Nuclear cotranslocation of β-catenin and TCF4 has been regarded
as the consequence of Wnt activation [27,30,35]. Of 54 gastric
samples compared here, some premalignant lesions and majority of
gastric cancers were found with this cotranslocation (Table 1 and
Figure 5A). Meanwhile, S100A4 was found in 21 of 27 GC samples
but only in 1 premalignant mucosum. Although a general correlation
of these two parameters could be established statistically (P = .039,
r = 0.313; Table 2), there were 13 (38%) of 34 cases with β-catenin/
TCF4 nuclear translocation but absence in S100A4 expression and 2
(8.7%) of 23 S100A4-positive GC cases without β-catenin/TCF4
nuclear translocation (Figure 5A). The in vitro study demonstrated
that both S100A4 expression and β-catenin/TCF4 nuclear translo-
cation were found in MGC803 and BGC823 cells, whereas the
cultured human fibroblasts expressed S100A4 in the absence of β-
catenin/TCF4 nuclear translocation (Figure 5B).
S100A4 Hypomethylation in GC Tissues and Cell Lines
The S100A4 gene does not contain CpG islands in the promoter
region, but methylation of critical CpG sites in the first intron reg-
ulated transcription of the S100A4 gene [39,21]. To determine the
Table 4. Correlations of S100A4 with Membranous E-cadherin and Nuclear β-Catenin Expression
in GCs.
S100A4 r P
− + ++ +++
E-cadherin − 7 5 3 0 −0.282 .043
+ 9 4 5 4
>++ 14 1 2 0
β-Catenin − 18 0 2 0 0.313 .024
+ 6 5 3 3
++ 4 2 4 0
+++ 3 4 0 0
Figure 4. Paralleled analyses of S100A4 and E-cadherin expressions in a glandular structure of i-GC tissues (A) and BGC823 cell line (B)
by IHC staining, RT-PCR, and Western blot analysis. Heterogeneous S100A4 expression and uniformly distributed E-cadherin could be
observed in (A), and coexistence of up-regulated S100A4 and membranous E-cadherin in (B). Original magnifications were ×25 for
tissues and ×40 for cultured cells.
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relation of DNA methylation status with S100A4 expression in GC
tissues and cell lines, PCR amplification and product sequencing
were performed on sodium bisulfite–modified DNA obtained from
7 noncancerous gastric mucosa, 6 S100A4-negative GC tissues (2 i-GCs
and 4 d-GCs), 12 S100A4-positive (7 i-GCs and 5 d-GCs), and 2 GC
cell lines. As shown in Table 5, all of the four CpG sites in the first
intron were methylated in the sample DNA of noncancerous gastric
mucosa and S100A4-negative GC tissues. In contrast, the guanine/G
molecules in the four CpG sites were replaced by adenine/A in
the DNA isolated from the S100A4-expressing GC tissues and GC
cell lines. A close correlation of S100A4 expression and CpG site
methylation was statistically established (P = .000). Figure 6 dem-
onstrates the methylation status of the third and the fourth CpG
sites in the first intron of noncancerous mucosum, cancer tissue,
and BGC823 cell lines. The same methylation patterns were found
in the first and the second CpG sites but not shown in Figure 6 be-
cause of the space limitation.
Discussion
Although the association of overexpressed S100A4 with metastasis
potential of gastric cancers has been described [23], the detailed
S100A4 expression pattern(s) during stepwise gastrocarcinogenesis
remains less known. Our IHC results are in line with the general
notion of the close link of S100A4 expression and GC dissemination
[9,23] by showing frequent S100A4 detection in primary GCs
(75%) and their lymph node metastases (100%). Further analysis
showed that the gastric epithelia of 18 GC-free patients were stained
Figure 5. (A) Fractionation of 52 gastric tissues (27 GCs and 25 premalignant lesions) used in this study according to their statuses of
S100A4 expression and β-catenin/TCF4 nuclear cotranslocation. (B) Immunohistochemical illustration of β-catenin, TCF4, and S100A4
expression in cancer cells and their surrounding stromal fibroblasts of an intestinal gastric cancer case. S100A4 ICC staining and double-
labeled immunofluorescent illustration of β-catenin (green) and TCF4 (red) performed on the coculture of human GC cell line (BGC823)
and normal fibroblasts and on the cultured normal fibroblasts. F indicates cultured fibroblasts; Ncl, nucleus; T , GC cells. Original mag-
nification, ×80.
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negatively in S100A4, suggesting the later appearance of S100A4 ex-
pression in the course of gastrocarcinogenesis. It has been known that
S100A4 can be expressed by the components of tumor stromal com-
ponents such as tumor-associated fibroblasts, lymphocytes, and endo-
thelial cells [24–26]. The case also holds true in premalignant and
cancer tissues of the stomach because of the frequent observation of
S100A4-positive cells in stromal components and tumor surrounding
tissues. For instance, S100A4 was expressed in the fibroblasts and lym-
phocytes of premalignant lesions such as atrophic gastritis, presumably
owing to the intrinsic [27] and/or inflammatory reason(s) as observed
in renal epithelia with chronic injuries [28]. The above findings thus
implicate 1) that S100A4-mediated parenchyma-stroma interplays
may occur as early as premalignant stage, 2) that S100A4-producing
stromal cells may play favorable roles in cancer promotion and progres-
sion as suggested by Emberley et al. [29], and 3) that the contamina-
tion of S100A4-positive stromal cells during sample preparation may
elevate the rates of S100A4 detection in Western blot analysis and,
especially, RT-PCR examination.
The status of S100A4 expression has been studied on many kinds
of cancers, but the detailed distribution patterns of this protein in
cancer tissues have rarely mentioned till recently. Agerbaek et al.
[30] reported the focal S100A4 expression in primary bladder cancers
and its predictive value in patients’ prognosis. According to our obser-
vation, d-GCs usually exhibit homogenous distribution of S100A4
protein, whereas S100A4 is distributed heterogeneously in i-GCs. In-
terestingly, this protein is allocated uniformly in all of lymph node
metastases irrespective of its distribution patterns in the corresponding
primary tumors. The above phenomena implicate that S100A4 may
confer on GC cells’ more aggressive behavior and selective advantage
for successful distant metastasis by the biological effects proposed by
many investigators [24,31,32]. The underlying reason(s) leading to the
heterogeneous S100A4 distribution remains obscure at current stage,
but it is unlikely caused by the so-called multiclonal GC formation
because of the heterogeneous S100A4 expression in the same cell clus-
ters or glandular structures of primary tumors. Alternatively, the highly
variable feature of S100A4 expression might indicate the influence(s)
of microenvironmental element(s), cell cycle regulators, and especially
epigenetic factor(s) in the transcription of this gene [33].
Alternative splicing is a universal posttranscriptional event, which
provides the basis of proteomic generation and functional diversity
Table 5. Methylation Statuses of the Four CpG Sites in S100A4 First Intron Among the Gastric
Tissues With (+) and Without (−) S100A4 Expression.
Group Case No. S100A4*
Hypermethylation Hypomethylation
S100A4−
Noncancerous† 7 7 0
GCs 6 6 0
S100A4+
GC tissues 12 0 12
GC cell lines 2 0 2
*Methylational modulations concurrently happen to the four CpG sites in the first intron.
†Gastric mucosa with mild chronic gastritis.
Figure 6. Representative PCR-generated sequences (in complementary pairing and reverse direction) of the S100A4 intron 1 from so-
dium bisulfate–treated DNA samples of S100A4-negative noncancerous mucosum (A), S100A4-positive GC tissue (B), and BGC803 cell
line (C) showing the third and fourth sites of CpG methylation in (A) for base C protected and hypomethylated in (B) and (C) for base C
transfer to T.
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of cells [10]. The ways of splicing are usually different between nor-
mal tissues and their malignant counterparts [34]. Alternative splicing
also happens to the S100A4 gene, and several splicing variants with
the sequence changes ahead of promoter region have been described
[11,12]. However, no data have been so far available about their bi-
ological and oncological implications. It has been recognized that the
ASs that occurred in the noncoding sequences of the gene transcripts
may not change the protein sequence but sometimes reflect cellular
alterations [34]. Therefore, the expression patterns of two relatively
stable S100A4 splicing variants [11] in different gastric tissues were
examined by checking the migration patterns of RT-PCR products in
polyacrylamide gel. In additional to the high frequency of S100A4
detection in GC samples, we found a 287-bp PCR product harbor-
ing Exons 1, 3, and 4 (AS1 variant) in premalignant lesions of some
GC cases as well as the endoscopic chronic gastritis of GC-free pa-
tients without stroma discrimination and an additional 9-bp shorter
product encompassing Exons 2, 3, and 4 (AS2 variant) in a great part
of GCs. These findings strongly suggest that AS2 is a unique splicing
isoform generated preferentially in GC cells and is therefore closely
associated with malignant transformation of gastric epithelial cells. It
is interesting that AS1 transcript is constantly expressed in S100A4-
positive cells irrespective of the cell types, whereas none of the tissue
samples so far checked has been found with a splicing pattern of
AS1-negative and AS2-positive (−/+). Given the evidence of the ab-
sence of AS1 and AS2 (AS1−/AS2−) in normal gastric mucosa, fre-
quent AS1 but not AS2 (AS1+/AS2−) in premalignant lesions, and
increased AS1 and AS2 detection (AS1+/AS2+) in GC tissues, it
would be possible that AS1 may be a highly conserved transcript
or a standard form of S100A4, whereas AS2 comes out as a later
event. To test this speculation, the origin(s) of AS1 and AS2 tran-
scripts in premalignant lesions of GC patients was clarified by RT-
PCR performed on the individual cell components. The AS1 variant
was generated from the lymphoid nodules and from the tonsil lym-
phocytes but not from the epithelial cells of premalignant lesions and
GC surrounding tissues. To ascertain these phenomena, IHC stain-
ing was performed on endoscopic mucosa, which showed immuno-
labeling only in the stromal lymphocytes and sporadically appeared
fibroblasts. These evidences prove largely 1) that normal gastric ep-
ithelial cells rarely express S100A4 and 2) that S100A4-expressing
stromal but not epithelial cells are responsible for the increased
RT-PCR detections of S100A4 in premalignant tissues. Therefore,
the data obtained from in situ IHC observation may provide more
reliable information. Conversely, both AS1 and AS2 variants were
detected in the cultured fibroblasts, suggesting that GC cells share
the capacity with fibroblasts to mutually exclude Exon 2 or Exon 1
during the process of splicing. Although it is difficult to predict the
biological significance of GC- or fibroblast-associated AS2 expres-
sion at the current stage, the high frequency of this variant in tumor
samples indicates, at least in part, that S100A4 AS2 may be one of
the representative global splicing abnormalities of gastric cancers.
The absence of AS1−/AS2+ splicing pattern may be caused by the
apparent existence of exon 1 on both splice variants and implicates
that the appearance of AS2 is the secondary event of S100A4 expres-
sion. This “exonomic” change may serve as a potential diagnostic and
prognostic biomarker of gastric cancer.
So far, the detailed molecular mechanism leading to disordered
S100A4 expression remains obscure. Several hypotheses have been pro-
posed to explain the onset of this unfavorable molecular event, which
include the potential inhibitory effect of E-cadherin on S100A4 ex-
pression [34], the targeting transcriptional activation of S100A4 by
Wnt signaling [15], and the epigenetic modulation of S100A4 expres-
sion through DNA methylation at the CpG sites in the first intron
of the S100A4 gene [12]. However, no paralleled correlative study
has been done to evaluate the influence of these three elements in
S100A4 expression. This issue was addressed in current study using
identical experimental gastric system.
E-cadherin has been known as metastasis-inhibitory protein by
forming intercellular junction [15]. Reduced E-cadherin expression
has been found in a variety of malignancies including GCs owing
to genetic and/or epigenetic reasons [13,14]. Inverse expression pat-
terns of S100A4 and E-cadherin are commonly found in different
cancers, but the casual relationship between these two alterations
has not yet been ascertained. Although our statistical analysis showed
this inverse correlation as well, the gain of S100A4 and loss of E-
cadherin did not always occur concurrently in gastric cancers. For
instance, the coexistence of S100A4 expression and intact membra-
nous distribution of E-cadherin was found in 15% (4/27) primary
GCs. In some cases, E-cadherin is distributed evenly in the glan-
dular structures of i-GCs but part of cells showed S100A4 expres-
sion. Besides, down-regulated E-cadherin could be observed in five
S100A4-negative GC cases. These data thus implicate the alternative
regulation of S100A4 expression in gastric cancer cells.
Nuclear translocation of β-catenin, another unfavorable molecular
event that happened during the later stages of gastrocarcinogenesis, is
considered as the consequence of inverse expressions of Wnt and E-
cadherin [35,36]. Recently, S100A4 was proposed as a target of Wnt
signaling because a β-catenin/TCF–binding site had been identified
in the S100A4 promoter sequence of cultured colon cancer cells [15].
However, in vivo correlative analysis of β-catenin/TCF nuclear trans-
location and S100A4 expression has not yet been available. Our
comparative analysis clearly revealed that these two alterations were
overlapped in 17 of 27 GCs, suggesting their importance in GC for-
mation and progression. We also noticed that S100A4 expression was
not necessarily accompanied with β-catenin/TCF nuclear transloca-
tion, because Wnt activation was absent in S100A4-positive premalig-
nant lesions as well as the stromal fibroblasts. The same situation could
also be found in the cultured human fibroblasts in which S100A4
was constitutively expressed irrespective of the absence of Wnt expres-
sion and β-catenin/TCF nuclear translocation. These findings thus in-
dicate the existence of additional regulatory machinery for S100A4
expression in premalignant gastric lesions and fibroblasts.
DNA methylation is the main machinery of epigenetic modula-
tion, which regulates the gain or the loss of gene transcription. Hy-
permethylation of tumor-suppressor genes and hypomethylation of
cancer-associated genes are common epigenetic phenomena in cancer
cells. In most types of normal cells, the S100A4 gene keeps silence
and becomes expressed when malignant transformation occurs to
those cells [3,37]. The data from prostate cancer, colon cancer, and
pancreatic cancer revealed that S100A4 expression was closely related
with hypomethylation of CpG sites in its first intron [15,38,39].
Given the evidence of S100A4 expression beyond E-cadherin down-
regulation and Wnt activation, the methylation status in that region
was checked using a panel of S100A4-negative and -expressing gastric
samples. It was clearly demonstrated that all of S100A4-expressing GC
tissues/cell lines were found with the hypomethylation of the four in-
tronic CpG sites, irrespective of the morphologic subtypes; in contrast,
those sites remain hypermethylated in the noncancerous gastric mu-
cosa and the six S100A4-negative GC tissues. Our current findings
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thus highlight the role of hypomethylation in regulating S100A4 ex-
pression in gastric cancers, although the consensus of intronic scattered
CpG site methylation with gene expression needs to be further con-
firmed by the use of DNA demethylators and/or methylators.
Collectively, this study demonstrated for the first time the distinct
S100A4 distribution patterns between some primary GCs and their
lymph node metastases, the differential S100A4 splicing patterns
among individual cell elements of gastric mucosa, the preferential
S100A4 AS2 expression in GC tissues and human fibroblasts, and
the absence of AS1−/AS2+ splicing pattern in different samples so
far checked. The above findings suggest that S100A4 expression
and, especially, the appearance of AS2 variant would have potential
values in the assessment of GC risk and prognosis. S100A4 expres-
sion is correlated but not always overlapped with E-cadherin down-
regulation and Wnt activation in gastric cancers. Nevertheless, the
status of CpG site methylation in the first intron was closely related
with the silence or the gain of S100A4 transcription, suggesting the
importance of this epigenetic factor in modulating S100A4 expres-
sion in gastric cancers. As the next step, the biological implication of
fibroblastlike splicing patterns of S100A4 in GC cells and the effect of
DNA demethylator on S100A4 expression will be investigated.
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